logo

For the Inventor, By the Inventor

Elmwood Park, NJ, United States of America

John M Wetzel

USPTO Granted Patents = 20 

 

Average Co-Inventor Count = 5.7

ph-index = 5

Forward Citations = 126(Granted Patents)


Location History:

  • Elmwood Park, NJ (US) (1995 - 2003)
  • Athens, OH (US) (2007)
  • Fairlawn, NJ (US) (2004 - 2009)

Company Filing History:

goldMedal14 out of 126 
 
Synaptic Pharmaceutical Corporation
 patents
silverMedal5 out of 506 
 
H. Lundbeck A/s
 patents
bronzeMedal1 out of 4 
 
H. Lunbeck A/s
 patents

Years Active: 1995-2009

Loading Chart...
Loading Chart...
20 patents (USPTO):Explore Patents
1. 7473698 - Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof (2009-01-06),
2. 7465750 - Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods (2008-12-16),
3. 7335665 - Spirocyclic piperidines as MCH1 antagonists and uses thereof (2008-02-26),
4. 7199135 - Substituted alkyl amido piperidines (2007-04-03),
5. 7166635 - 3-imino-2-indolones for the treatment of depression and/or anxiety (2007-01-23),
6. 7105544 - Substituted alkyl amido piperidines (2006-09-12),
7. 7067534 - Substituted anilinic piperidines as MCH selective antagonists (2006-06-27),
8. 6727264 - Substituted anilinic piperidines as MCH selective antagonists (2004-04-27),
9. 6720324 - Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof (2004-04-13),
10. 6706716 - Compounds specific for the human &agr;1d adrenergic receptor and uses thereof (2004-03-16),
11. 6608086 - Dihydropyridines and new uses thereof (2003-08-19),
12. 6602888 - Use of &agr;1C specific compounds to treat benign prostatic hyperplasia (2003-08-05),
13. 6310076 - Dihydropyridines and new uses thereof (2001-10-30),
14. 6211198 - Dihydropyridines and new uses thereof (2001-04-03),
15. 6015819 - Use of alpha-1C specific compounds to treat benign prostatic hyperplasia (2000-01-18),

Title: The Innovative Mind of John M Wetzel

Introduction:

John M Wetzel, a prolific inventor based in Elmwood Park, NJ, has made significant contributions to the field of pharmaceuticals with a total of 20 patents to his name. His groundbreaking inventions have focused on developing compounds for treating various disorders, showcasing his brilliance in the realm of scientific innovation.

Latest Patents:

One of Wetzel's latest patents involves the creation of Secondary amino anilinic piperidines as MCH1 antagonists, targeting melanin concentrating hormone-1 receptors. This invention introduces a pharmaceutical composition that effectively treats depression, anxiety, and urinary disorders. Additionally, his work on GAL3 antagonists for depression and anxiety treatment illustrates his commitment to improving mental health through innovative pharmaceutical solutions.

Career Highlights:

Wetzel's career highlights include his tenure at Synaptic Pharmaceutical Corporation and H. Lundbeck A/S, where his expertise and inventive spirit flourished. His patents reflect a deep understanding of pharmacology and a relentless drive to discover novel therapeutic compounds that can enhance the well-being of individuals worldwide.

Collaborations:

Throughout his career, Wetzel has collaborated with esteemed professionals in the field, such as Charles Gluchowski and George Chiu. These collaborations have enriched his inventions, leading to groundbreaking discoveries that have the potential to revolutionize the pharmaceutical industry.

Conclusion:

John M Wetzel's innovative work in pharmaceuticals stands as a testament to his ingenuity and dedication to advancing medical science. His patents not only demonstrate his technical prowess but also highlight his unwavering commitment to improving the lives of individuals through pioneering pharmaceutical solutions. Wetzel's legacy as an inventive mind in the field of science continues to inspire future generations of innovators in the pursuit of transformative healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…